We are thrilled to share exciting news about our recent success in fundraising, marking a crucial milestone in our journey towards transforming musculoskeletal health on a global scale.
In 2023, Kinexcs, your go-to healthtech firm for innovative musculoskeletal solutions, secured a whopping S$4.1 million in funding during its Pre-Series A round. This fantastic achievement positions us for an exhilarating year of expansion and innovation in 2024.
Who’s Behind the Support?
Pureland Ventures and Enterprise Singapore led the charge, joined by prominent investors from three continents. Their belief in our mission speaks volumes, with contributors including ParticleX, Govin Capital, NGEN Capital, SeedTree Ventures, SOSV Ventures, and several high-net-worth angel investors.
Our Vision Unveiled:
At Kinexcs, our mission is to enable and empower people for better mobility and an enhanced quality of life. Abhishek Agrawal, our CEO and Co-Founder, emphasized that the recent funding round solidifies support for this global mission.
Where Will the Funds Go?
The allocated funds are strategically earmarked for two critical areas:
1. Market Entry and Growth:
We’re spreading our wings in high-potential markets, focusing on Singapore, Hong Kong, Malaysia, Thailand, India, the US, Canada, Germany, Netherlands, Switzerland, and the UK. Immediate, mid-to-long-term, and long-term growth plans are in place to tap into the vast, untapped potential in these regions.
2. Talent Acquisition and Innovation:
Expect exciting developments as we bring in top-tier talent to bolster our R&D, product development, and market expansion efforts. This infusion of expertise will enhance our existing AI-powered solutions, including KIMIA® Recover, KIMIA® Assess, and KIMIA® Deskercise.
Celebrating Our Achievements:
Kinexcs boasts an impressive track record:
- Quadrupling revenue since our last financial year.
- Securing FDA approval for our flagship product, demonstrating our commitment to the highest regulatory standards.
- Earning accolades such as Forbes 100 in Asia, SLINGSHOT Singapore 2nd runner-up, NHIC I2I grant selection, and the Johnson & Johnson QuickFire Challenge Award.
What’s Next?
This strategic funding, coupled with our growth strategy, positions Kinexcs as a disruptive force in the MSK digital health landscape. With cutting-edge technology and a patient-centric approach, we’re poised to shape the future of MSK care, benefiting both patients and healthcare providers.
Looking Ahead:
As we chart our course for the future, we’re committed to reaching seven figures in revenue in the next year. Stay tuned as we gear up for a Series A round, showcasing our unwavering commitment to unlocking transformative possibilities in the global MSK rehabilitation market.
Join Us on this Exciting Journey:
We invite you to be a part of our community as we continue to pioneer advancements in digital health solutions. For inquiries or more information, reach out to info@kinexcs.com.
At Kinexcs, we’re not just transforming musculoskeletal health; we’re empowering lives. Thank you for being part of our incredible journey!
